Biotronik GmbH launched the Lumax 540 series, which includes implantable cardioverter defibrillators (ICDs) and a cardiac resynchronization therapy defibrillator (CRT-D), which is used with Biotronik Home Monitoring to enable continuous automatic daily data transmission of the patient’s cardiovascular status via the Internet.
The Lumax 540 series has the SelectSense features, which has various presettings to adapt sensing characteristics to individual patient needs to ensure accurate arrhythmia detection. The Defibrillation Threshold Manager is to assure life-saving shock therapy delivered successfully. In addition, the Automatic Threshold Monitor performs daily threshold measurements. The Heart Failure Monitor detects changes in heart failure conditions with a range of clinical predictors.
A set of diagnostic capabilities are included in the Lumax 540 devices help physicians with the identification of atrial fibrillation and the early detection of worsening heart failure status. The Lumax 540 devices offer the combination of tachycardia therapy management, diagnostic capabilities and remote monitoring technologies.
Biotronik’s batteries are said to extend the life of the Lumax 540 devices up to 10 years.
July 31, 2024 
